Skip to main content

ASCIA Submissions 2025

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

19 May 2025: A joint communication to the TGA was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council in support of neffy® adrenaline devices.

19 May 2025: A joint communication to the TGA was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council in support of neffy® adrenaline devices to be available as Schedule 3 medications in Australia.

9 April 2025: A joint communication was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council to Virgin Australia Ltd, regarding the proposed amendment to allow airline passengers to travel with companion dogs and cats in the aircraft cabin. Virgin Australia has provided a detailed response.

27 March 2025: ASCIA submitted a new application to the Medical Services Advisory Committee (MSAC) for a Medical Benefits Schedule (MBS) item number for supervised oral food challenges (OFC), as part of the National Allergy Council projects that are assigned to ASCIA. 

10 March 2025: A joint communication was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council to the Hon Mark Butler MP, Minister for Health and Aged Care, Parliament of Australia, regarding Telehealth Post-Implementation Review Final Report - Recommendation 10a.

10 March 2025: ASCIA lodged a letter of support for the following Medical Services Advisory Committee (MSAC) application by the Royal College of Pathologists of Australasia (RCPA) for genomic testing for the diagnosis of inborn errors of immunity (IEI) including primary immunodeficiency diseases (PID). 

10 March 2025: ASCIA lodged a letter of support for the following application, for review at the May 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting:

24 February 2025: A joint communication was submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding the importance of amino acid formula being listed on the PBS for patients with cow’s milk allergy, from ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council.

20 February 2025: ASCIA responded to a survey conducted by HealthConsult on behalf of the National Blood Authority (NBA) regarding the development of the Ig Prioritisation Framework (the Framework), which will guide decision-making and allocation of immunoglobulin (Ig) in the event of a supply shortage.

17 February 2025: A joint communication was submitted to the ACT Government regarding the need for a public paediatric allergy clinic in the ACT, from ASCIA, Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council.

23 January 2025: ASCIA lodged five letters of support on  for the following applications, for review at the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting:

January 2025: ASCIA provided two letters of support for allergy/immunology departments to the World Allergy Organisation (WAO) Center pf Excellence program. 

Read more …ASCIA Submissions 2025

ASCIA Submissions 2024

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA submitted a response on 7 October 2024 to the Royal Australasian College of Physicians (RACP) call for feedback on the Development of the Clinical Immunology and Allergy Advanced Training Curriculum. This was an opportunity to review and provide professional insights, with the redesign enabling development of best practice education and assessment models. In compiling this feedback ASCIA sought input from the ASCIA Directors and Chairs of the Adult Practice, Anaphylaxis, Drug Allergy, Immunodeficiency and Paediatric Practice Committees. Emails from ASCIA were also sent to ASCIA Full and Associate Trainee members, in case they wished to provide feedback directly to the RACP.
    pdfASCIA letter RACP 07 OCT 2024192.75 KB
  • ASCIA lodged four confidential submissions on 9 July 2024 regarding PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis for consideration at the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting under "Other Matters (Change to existing listing)". The PBAC outcomes for the July 2024 meeting are on the PBS website: pbac-web-outcomes-07-2024.pdf (pbs.gov.au) and the entry for dupilumab is on page 28. Submissions were made to the PBAC, Sanofi, the Health Minister and the Assistant Health Minister.
    pdfASCIA letter PBAC DUPIXENT 2024-07-09110.13 KB

Read more …ASCIA Submissions 2024

ASCIA Submissions 2023

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA statement on clinical need to maintain supply of VIT for bees and wasps submitted to Pharmac NZ. Lodged  13 October 2023.
  • ASCIA response to PBS post marketing investigation of the use of omalizumab in chronic spontaneous urticaria. Lodged 19 September 2023.
  • ASCIA submission to ACECQA for approval of ASCIA anaphylaxis e-training for children's education and care. Lodged 1 September 2023. ACECQA approval has been confirmed until  October 2026. Read more here 

  • ASCIA submission in response to the Food Standards Australia New Zealand (FSANZ) call for submissions on Proposal P1028 – Infant Formula.  Submission lodged 13 July 2023.

    pdfASCIA FSANZ P1028 Response July 2023258.66 KB

  • ASCIA submissions on 23 May 2023 in support of two products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

pdfASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 pdfASCIA letter PBAC Dupilumab 2023 05 2367.24 KB

  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.
  • ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.
  • ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

Read more …ASCIA Submissions 2023

ASCIA Submissions 2022

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
    pdfASCIA supports HGSA MSAC application 20221007
  • ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
    pdfASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here
  • Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.
  • Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 
  • ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 
  • Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
    pdfASCIA letter PBAC Dupilumab 2022 01 1352.73 KB
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

Read more …ASCIA Submissions 2022

ASCIA Submissions 2021

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

Read more …ASCIA Submissions 2021

More Articles …